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Abstract: Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence 
of ischemic events in patients with acute coronary syndromes and those undergoing percutane-
ous coronary intervention. A minority of patients given eptifibatide develop acute, profound 
thrombocytopenia (,20,000 cells/mm3) within a few hours of receiving the drug. This case 
report discusses a patient who developed profound thrombocytopenia within hours of receiving 
eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient’s 
thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an 
uncommon but clinically important complication of eptifibatide. This case report emphasizes 
the importance of monitoring platelet counts routinely at baseline and within 2–6 hours of 
eptifibatide administration.
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Introduction
Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by 
inhibiting the binding of fibrinogen to activated platelet glycoprotein IIb/IIIa recep-
tors, thereby inhibiting platelet–platelet interaction and thrombus formation. Eptifi-
batide is part of the antithrombotic therapy used to prevent occlusion of the coronary 
  arteries, thus reducing the incidence of ischemic events in patients with acute coro-
nary syndromes and those undergoing percutaneous coronary intervention.1,2 While 
eptifibatide has significantly improved outcomes in patients undergoing percutaneous 
coronary intervention and among those presenting with an acute coronary syndrome, 
a small number of patients given eptifibatide develop acute profound thrombocytope-
nia (,20,000 cells/mm3) within a few hours of receiving the drug that can increase 
the risk of serious bleeding and, in some rare cases, induce thrombosis.3–5 Profound 
thrombocytopenia is an uncommon but clinically important complication of glycopro-
tein IIb/IIIa inhibitors. This case report discusses a patient who developed profound 
thrombocytopenia within hours of first administration of eptifibatide.
Case report
A 42-year-old Caucasian female with no previous history of cardiovascular disease 
presented to the emergency department with a two-hour history of substernal chest pain 
that felt crushing in nature and radiated to the left arm and left jaw. Her past medical 
history included chronic back pain from a road traffic accident and an outpatient tubal 
ligation. She denied any previous history of blood dyscrasia or thrombocytopenia. Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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She had smoked two packs of cigarettes per day for the last 
28 years. Her family history was significant for her brother 
having had a stroke. She reported that she was not taking 
any medications prior to admission. Additionally, she denied 
any history of a previous hospitalization where she may have 
received heparin or eptifibatide.
At presentation, her electrocardiogram showed inferior 
and lateral ST elevation. Initial cardiac markers were creatine 
kinase (CK) 407 ng/mL (38–120 ng/mL), CK myoglobin 
(CK Mb) 2.5 ng/mL (0 –3 ng/mL), troponin I , 0.05 ng/mL 
(0–0.02 ng/mL), and myoglobin 54 ng/mL (0–66 ng/mL). 
Complete blood count obtained at the time of presentation 
included a white blood cell count of 8.9 × 109/L (normal range 
4.1–10.9 × 109/L), hemoglobin 14.3 g/dL (12–15.2 g/dL for 
women), hematocrit 41.6% (37%–46% for women), and 
platelet count 220 × 109/L (140–450 × 109/L). A complete 
metabolic panel drawn at the same time included serum 
creatinine 0.92 mg/dL, glucose 148 mg/dL (70–100 mg/dL), 
and electrolytes were within normal limits.
The patient was initiated on aspirin 325 mg po daily, 
lisinopril 5 mg po daily, metoprolol succinate 50 mg po daily, 
clopidogrel 300 mg × 1 dose then 75 mg po daily, an intra-
venous heparin infusion and atorvastatin 80 mg po daily. 
Within 90 minutes of presentation, she was sent to the cardiac 
catheterization laboratory for primary percutaneous coro-
nary intervention. Angiography revealed a 100% distal-mid 
occlusion in the right coronary artery, a 40%–50% stenosis 
of the mid left anterior descending coronary artery, and a 
75% stenosis of the mid circumflex artery. Before percuta-
neous coronary intervention, a double bolus of intravenous 
eptifibatide (180 µg/kg 10 minutes apart) was delivered fol-
lowed by initiation of an eptifibatide infusion at 2 µg/kg/min. 
The patient also had the heparin infusion discontinued and 
received a 60 U/kg bolus heparin injection, resulting in an 
activated clotting time of 225 seconds. The patient then 
underwent successful stenting of the right coronary artery 
with a sirolimus-eluting stent. Once flow was restored, the 
patient became pain-free and had resolution of ST segment 
elevation. She was transferred in a stable condition to the 
coronary care unit for aggressive secondary prevention of 
her coronary artery disease. Post-percutaneous coronary 
intervention medications included aspirin 325 mg po daily, 
lisinopril 5 mg po daily, metoprolol succinate 50 mg po daily, 
clopidogrel 75 mg po daily, atorvastatin 80 mg po daily, and 
the eptifibatide infusion was to be continued for 18 hours.
Approximately four hours post-percutaneous   coronary 
intervention and eptifibatide initiation, the patient   developed 
a precipitous thrombocytopenia, with her   platelet count 
  dropping by over 90% from baseline to 17 × 109/L (see   Figure 1). 
A peripheral blood smear showed no signs of platelet clump-
ing, ruling out pseudothrombocytopenia. The rest of her 
  complete blood count at this time included hemoglobin 
10.7 g/dL, hematocrit 31.3%, and white blood cell count 
6 × 109/L. Eptifibatide was subsequently discontinued. 
The patient’s platelet level reached its nadir (13 × 109/L) 
approximately nine hours post-eptifibatide initiation. 
The patient’s platelet count gradually climbed, and was 
71 × 109/L at the time of discharge (approximately 80 hours 
post-eptifibatide initiation). The patient showed no signs of 
active bleeding, bruises, ecchymosis, or petechiae during 
the hospitalization.
One month later, the patient underwent elective percu-
taneous coronary intervention of her circumflex artery. Her 
platelet count at the time of the procedure was 142 × 109/L. 
Bivalirudin was used during the percutaneous coronary 
intervention as an alternative to heparin and eptifibatide. She 
experienced no reductions in platelet count during the admis-
sion and was found to have a platelet count of 180 × 109/L at 
her two-month follow-up clinic visit.
Discussion
Drug-induced immune thrombocytopenia is an unpredict-
able and sometimes serious side effect of many medications, 
including heparin, quinine, nonsteroidal anti-inflammatory 
drugs, sulfonamides, and other antibiotics, especially vanco-
mycin, rifampicin, and cephalosporins.6,7 Platelet destruction 
is usually caused by drug-induced antibodies generated after 
drug exposure. The predominant pattern is an uneventful 
first exposure to a drug, then an acute drop in platelet count 
on   re-exposure. Thrombocytopenia induced by the glyco-
protein IIb/IIIa antagonist, eptifibatide, does not adhere to 
this pattern.
There are three clinically approved glycoprotein IIb/IIIa 
antagonists, ie, abciximab, eptifibatide, and tirofiban. These 
agents are similar in that they all inhibit platelet aggrega-
tion by blocking platelet–fibrinogen interaction via the 
glycoprotein IIb/IIIa receptor. Abciximab is associated 
with a higher incidence of thrombocytopenia than eptifi-
batide and tirofiban, and predominantly more often fits the 
usual pattern of drug-induced immune thrombocytopenia.8 
Thrombocytopenia is seen in about 1% of patients given 
abciximab for the first time, while acute and more profound 
thrombocytopenia develops within a few hours in more 
than 10% of those treated a second time.9–12 Abciximab is 
a Fab fragment of the chimeric human-murine monoclonal 
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Most people in the healthy population have pre-existing 
antibodies to the human Fab portion of abciximab, although 
this does not appear to play a major role in thrombocy-
topenia. Patients who develop profound thrombocytopenia 
develop antibodies specific for the murine 7E3 fragment 
upon drug exposure.13,14 This explains the high incidence of 
profound thrombocytopenia on re-exposure to   abciximab. 
Although most patients with abciximab-associated 
thrombocytopenia recover uneventfully, life-threatening 
bleeding, including intracranial hemorrhage, has been 
described.11,14
Eptifibatide is a ligand-mimetic drug that competitively 
inhibits the glycoprotein IIb/IIIa receptor. Eptifibatide binds 
specifically to the Arg-Gly-Asp recognition site on glyco-
protein IIb/IIIa, thereby rendering the glycoprotein IIb/IIIa 
receptor incapable of binding fibrinogen. The incidence of 
acute profound thrombocytopenia with eptifibatide has been 
reported to be 0.2%–1.0%.1,2,15 As opposed to abciximab, 
patients may develop acute profound thrombocytopenia 
(platelet count ,20,000/mm3) upon primary exposure 
to eptifibatide. Of the 22 reported cases in the literature, 
only five patients had   previous exposure to eptifibatide 
and three had exposure to abciximab.5 The binding of 
eptifibatide to the glycoprotein IIb/IIIa receptor may 
induce a   conformational change in the   receptor, creating 
  ligand-induced   binding sites.16 Some healthy individuals 
have strong naturally occurring   antibodies that recognize 
these ligand-induced binding sites and are capable of having 
severe and sometimes life-  threatening thrombocytopenia 
following drug   administration.16 These antibodies can be 
identified in most patients’ blood samples obtained prior 
to treatment with eptifibatide, affirming that they can be 
naturally occurring.16 A variety of assays have been used 
to show that most patients developing thrombocytopenia 
after eptifibatide administration have antibodies that rec-
ognize glycoprotein IIb/IIIa occupied by the drug.16–18 On 
the other hand, patients who receive eptifibatide and do 
not have antibodies of this type do not experience pro-
found thrombocytopenia.16 Because thrombocytopenia in 
patients who have received eptifibatide is usually caused 
by pre-existing antibodies, pretreatment screening for 
pre-existing antibodies has been proposed to reduce the 
incidence of eptifibatide-induced thrombocytopenia, but 
improvements in antibody detection are needed before this 
practice becomes routine.17
Treatment with glycoprotein IIb/IIIa antagonists has also 
been associated with pseudothrombocytopenia, an artifactual 
finding suspected initially by finding platelet clumping on a 
blood smear.19 It has been shown to account for over one-third 
of cases of thrombocytopenia during glycoprotein IIb/IIIa 
inhibitor therapy.19 It is of no clinical relevance, but must 
be ruled out so that glycoprotein IIb/IIIa antagonist therapy 
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is not unnecessarily discontinued. Pseudothrombocytopenia 
was ruled out in this patient because there was no platelet 
clumping observed on peripheral blood smear.
The patient in this report was exposed to several agents 
during her admission that have been associated with profound 
thrombocytopenia. Heparin is well known to precipitate 
thrombocytopenia, but the published literature to date sug-
gests that a previous exposure is required, similar to the 
reaction seen with heparin-induced thrombocytopenia.20 
Heparin-induced thrombocytopenia type I is characterized by 
a mild and transient asymptomatic thrombocytopenia (rarely 
,100,000 platelets/mm3) that develops early   (usually within 
the first two days of starting heparin).20 Heparin-induced 
thrombocytopenia type II is immune-mediated and associ-
ated with a risk of thrombosis. In patients receiving heparin 
for the first time, the onset of thrombocytopenia usually 
occurs 5–10 days after the administration of the   heparin.20 
The platelet drop can be seen within hours in patients with 
pre-existing heparin/platelet factor 4 antibodies from a pre-
vious exposure.20 Our patient’s drop in platelet count was 
more severe than would be expected with heparin-induced 
thrombocytopenia type I. Additionally, the patient had no 
previous exposure to heparin and the timeframe of the decline 
in platelets does not fit heparin-induced thrombocytopenia 
type II. This makes it difficult to attribute our patient’s throm-
bocytopenia to heparin and, due to a low clinical suspicion 
of heparin-induced thrombocytopenia, serologic tests were 
not performed.
Thrombotic thrombocytopenic purpura can occur 
after the initiation of clopidogrel therapy, often within 
the first two weeks of treatment.21 Clopidogrel-induced 
thrombotic thrombocytopenic purpura is characterized 
by the presence of microangiopathic hemolytic anemia, 
thrombocytopenia, fever, neurologic manifestations, and 
renal insufficiency.21 Other than thrombocytopenia, our 
patient did not manifest any of the hallmarks of throm-
botic thrombocytopenic purpura and only received one 
300 mg dose of clopidogrel six hours before the observed 
drop in platelet count. It is unlikely that clopidogrel 
played a role in the development of thrombocytopenia 
in our patient.
The Naranjo algorithm classified the likelihood that 
the thrombocytopenia was related to eptifibatide as 
probable.22 Naranjo scores with heparin and clopidogrel 
were 1, indicating that these agents were possible, but 
most likely doubtful, causes of thrombocytopenia in this 
patient.22
Conclusion
Profound thrombocytopenia is an uncommon but clinically 
important complication of eptifibatide. Thrombocytopenia 
occurring after first exposure to eptifibatide appears to be 
explained by the fact that antibodies are naturally present in 
some individuals. Assays for pretreatment screening for pre-
existing antibodies are available, but are not yet established 
for regular use. This case report emphasizes the importance 
of monitoring platelet counts routinely at baseline and within 
2–6 hours of eptifibatide administration.
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